DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
ODM-201 is an investigational drug.
There have been 41 clinical trials for ODM-201. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Parkinson Disease, and Motor Neuron Disease. The leading clinical trial sponsors are Orion Corporation, Orion Pharma, Bayer, and University of Nottingham.
There are six US patents protecting this investigational drug and eighty international patents.
Recent Clinical Trials for ODM-201
|Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)||Sir Mortimer B. Davis - Jewish General Hospital||Phase 2|
|Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension||Orion Corporation, Orion Pharma||Phase 3|
|Safety and Pharmacokinetics of ODM-209||Orion Corporation, Orion Pharma||Phase 1/Phase 2|
Top disease conditions for ODM-201
Top clinical trial sponsors for ODM-201
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ODM-201||See Pricing||Carboxamide derivative and its diastereomers in stable crystalline form||Orlon Corporation (Espoo, FI)||See Pricing|
|ODM-201||See Pricing||Androgen receptor modulating compounds||ORION CORPORATION (Espoo, FI)||See Pricing|
|ODM-201||See Pricing||Process for the preparation of androgen receptor antagonists and intermediates thereof||Orion Corporation (Espoo, FI)||See Pricing|
|ODM-201||See Pricing||Androgen receptor modulating carboxamides||Orion Corporation (Espoo, FI)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ODM-201||European Patent Office||3250554||2035-01-30||See Pricing|
|ODM-201||World Intellectual Property Organization (WIPO)||2016120530||2035-01-30||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|